Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP4 | P49662 | 1/20 | 0.40 |
| ▸ | CASP5 | P51878 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605021 | 0.86 | HTR6 (0.62) | HRH4HTR6HRH3HTR3A | |
| SCHEMBL4364988 | 0.85 | ALDH1A1 (0.43) | HRH4HTR6ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL604044 | 0.80 | HRH4 (0.69) | HRH4HTR6HRH3ADCY10 | |
| SCHEMBL604043 | 0.80 | HRH4 (0.69) | HRH4HTR6HRH3ADCY10 | |
| SCHEMBL602529 | 0.80 | HRH4 (0.65) | HRH4HRH3ADRB1 | |
| SCHEMBL605097 | 0.79 | HRH4 (0.56) | HRH4HTR6HRH3CASP1CASP4 | |
| SCHEMBL603836 | 0.78 | HRH4 (0.52) | HRH4HRH3CASP1CASP4CASP5 | |
| SCHEMBL604865 | 0.78 | HRH4 (0.70) | HRH4HRH3 | |
| SCHEMBL604866 | 0.78 | HRH4 (0.70) | HRH4HRH3 | |
| SCHEMBL604231 | 0.77 | HRH4 (0.59) | HRH4HTR6HRH3ADCY10HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2599386-A1 | 2-aminopyrimidine modulators of the histamine h4 receptor | Janssen Pharmaceutica N.V. (BE) | 2013-06-05 | — | — | EP | claimed |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janseen Pharmaceutiacal NV | 2011-09-08 | — | — | US | claimed |
| EP-2124560-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | claimed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | HRH4 1/4885HTR6 67/4885HRH3 3/4885 |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | HRH4 1/4885HTR6 243/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.